- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06341036
Aetiology And Outcome Of Children With Thrombocytosis Admitted to Assiut University Children Hospital
Study Overview
Status
Conditions
Detailed Description
Thrombocytosis, also called thrombocythemia, is generally defined as a platelet count that is above the upper limit. The most commonly accepted cutoff value for normal is <450,000/μL. Platelet counts in the range of 450,000 to 700,000/μL are considered mild, between 700,000 and 900,000 /μL are considered moderate, between 900,000 and 1,000,000/μL are considered severe, and values above 1,000,000/μL are considered extreme thrombocytosis.The incidence of newly diagnosed primary thrombocytosis in children is about 1 per 10 million, about 60 times lower than adults.
The thrombocytosis is classified into primary thrombocytosis and secondary thrombocytosis. primary thrombocytosis classified into hereditary thrombocytosis which due to mutations in THPO,MPL,JAK2 and acquired primary thrombocytosis which classified into BCR-ABL1negative MPN as :Essential thrombocythemia(ET) , polycythemia vera(pv) ,primary myelofibrosis(PMF).and BCR-ABL1positive disorders but secondary thrombocytosis is due to :bacterial/viral infection,acute phase response ,chronic inflammation ,iron deficiency anemia , hemolytic anemia ,asplenia ,drugs :THPO analoga ,EPO.
Secondary thrombocytosis is commonly seen in children with a variety of clinical conditions. The most common cause of secondary thrombocytosis in children is respiratory infection .According to the World Health Organization guidelines, the persistent diagnosis of essential thrombocythemia requires a platelet count of ≥450,000/μL in patients with thrombocytosis, and it should be determined whether thrombocytosis is primary or secondary. The criteria of the World Health Organization are often used for diagnosis. .
In most cases, the symptoms are due to an underlying disorder and not the thrombocytosis itself. Extreme thrombocytosis may rarely result in thrombotic events such as acute myocardial infarction, mesenteric vein thrombosis, and pulmonary embolism.
The pathophysiology of thrombocytosis is according to each type:
Hereditary forms of primary thrombocytosis are caused by germline mutations within the genes encoding thrombopoietin (THPO), its receptor (MPL), and the receptor's effector kinase Januskinase2 (JAK2) .
Acquired primary thrombocytosis is marked by somatic mutations and occurs in several myeloid malignancies that are more commonly found in adults than in children. Therefore, most of the current knowledge on their pathogenesis and on their clinical management has been derived from studies in adults. Myeloid malignancies that may involve acquired primary thrombocytosis include myeloproliferative (MPNs) and myelodysplastic neoplasms (MDS), such as Philadelphia-positive chronic myeloid leukemia (CML), the Philadelphia-negative neoplasms ET, PV, and PMF, MPN/MDS with ring sideroblasts and thrombocytosis (RARS-T) or MDS with isolated del(5q) syndrome In secondary thrombocytosis , elevated platelet levels result from an extrinsic process, such as acute or chronic inflammation, which stimulates megakaryocytopoiesis . Thrombopoiesis is regulated by the interplay between thrombopoietin (THPO) and its receptor c-Mpl .In secondary thrombocytosis, interleukin-6 (Il-6) constitutes an additional key mediator .
Study Type
Enrollment (Estimated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
all patients from age 1 month to 18 years old , who were admitted to Assiut University Children's Hospital with thrombocytosis
Exclusion Criteria:
1-Neonates ,Children with malignancy , 2_Children with polycythemia vera
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Aetiology And Outcome Of children with Thrombocytosis admitted to Assiut University children hospital
Time Frame: Basalin
|
Patient will be classified into two groups according to type primary and secondary. Each group will be compared :
|
Basalin
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Thrombocytosis in Children
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thrombocytosis in Children
-
Taipei Medical University WanFang HospitalCompleted
-
Universitair Ziekenhuis BrusselCompletedHospitalization in ChildrenBelgium
-
The University of Texas Health Science Center,...WithdrawnHospitalism in ChildrenUnited States
-
Hacettepe UniversityCompleted
-
University Children's HospitalCompletedPropofol Anesthesia in ChildrenSerbia
-
University of British ColumbiaCompletedThreonine Requirements in ChildrenCanada
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedFiberoptic Intubation in ChildrenUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedLaryngeal Masks in ChildrenUnited States
-
Shriners Hospitals for ChildrenCompletedEnergy Expenditure in Burn Children | Protein Turnover in Burn ChildrenUnited States
-
University of Wisconsin, MadisonCompleted